azimexon has been researched along with Leukemia L 1210 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mathe, G | 1 |
| Bicker, U | 1 |
| Chirigos, MA; Lauer, L; Papademetriou, V; Stylos, WA | 1 |
1 review(s) available for azimexon and Leukemia L 1210
| Article | Year |
|---|---|
Experience gained in immunotherapy from the immunopharmacology of BCG leading to a second generation of systemic immunity adjuvants.
Topics: Adjuvants, Immunologic; Animals; Aziridines; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Immunologic; Humans; Immunotherapy; Leucine; Leukemia L1210; Leukemia, Lymphoid; Levamisole; Lymphoma, Non-Hodgkin; Melanoma; Methotrexate; Mice; Neoplasms; Propionibacterium acnes; T-Lymphocytes, Regulatory; Thymosin | 1980 |
2 other study(ies) available for azimexon and Leukemia L 1210
| Article | Year |
|---|---|
Therapeutic effects of BM 12,531 (Prop. INN azimexon).
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Aziridines; Azirines; Bacterial Infections; Cyclophosphamide; Female; Leukemia L1210; Mice | 1980 |
The immunomodulatory effect on BM 12.531 (azimexon) on normal or tumored mice: in vitro and in vivo studies.
Topics: Animals; Ascitic Fluid; Aziridines; Azirines; Cells, Cultured; Hypersensitivity, Delayed; Immunity, Cellular; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; X-Rays | 1980 |